logo
GLP-1s may offer better dementia protection than metformin

GLP-1s may offer better dementia protection than metformin

There were about 589 million adults around the world living with diabetes in 2024, with 90% having type 2 diabetes. Past studies have shown that people who have type 2 diabetes are at a higher risk of developing dementia. A new study has found that when it comes to the neuroprotective abilities of diabetes medications, people taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin users.The International Diabetes Federation reports there were about 589 million adults around the world living with diabetes in 2024, with 90% of these having type 2 diabetes. Past studies show that people who have type 2 diabetes — a chronic condition where the body does not use its insulin properly — are at a higher risk of developing dementia. 'Type 2 diabetes is not only a metabolic disorder but also a major risk factor for dementia, particularly Alzheimer's disease and other nonvascular dementias,' Szu-Yuan Wu, MD, MPH, PhD, professor of radiation oncology and pharmacoepidemiology at Asia University, and director of the Big Data Center at Lo-Hsu Medical Foundation at Lotung Poh-Ai Hospital, both in Taiwan, told Medical News Today.'The risk of developing dementia is approximately 1.7 times higher in individuals with type 2 diabetes than in the general population. This imposes significant burdens on families and healthcare systems,' Wu explained.He is first and co-senior author of a new study recently published in the journal BMJ Open Diabetes Research & Care.The study found that when comparing the neuroprotective abilities of two diabetes medications — metformin and glucagon-like peptide-1 receptor agonists (GLP-1 agonists) — participants taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin. Comparing GLP-1s, metformin head-to-headFor this study, researchers analyzed electronic health record data from the global health research network TriNetX. Scientists focused on data from more than 87,000 people with an average age of 58 who had type 2 diabetes and were prescribed either metformin or a GLP-1 agonist, to track any dementia development. 'Although metformin is widely accepted as the first-line therapy for type 2 diabetes, its effects on cognitive outcomes have been inconsistent,' Wu said. 'We aimed to investigate whether starting with a second-line agent like GLP-1 agonists might confer greater protective effects against dementia.'No previous real-world study has directly compared GLP-1 agonists and metformin head-to-head for dementia prevention,' he continued. 'If GLP-1 agonists show superior neuroprotective benefits, this could challenge the traditional treatment paradigm and support initiating therapy with GLP-1 agonists in selected patients.''GLP-1 agonists have demonstrated mechanisms that include reducing neuroinflammation, enhancing cerebral glucose metabolism, and improving synaptic plasticity,' Wu added. 'Given these benefits, it is imperative that we continue exploring their broader therapeutic potential beyond glucose lowering.'GLP-1s lower Alzheimer's risk by 12% compared to metforminAt the study's conclusion, Wu and his team found that study participants taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia — namely, 10% — with an incidence of about 2.5%.By comparison, the dementia incidence rate for those taking metformin was almost 5%. 'This nearly twofold difference in dementia incidence is clinically significant,' Wu explained.'It suggests that initiating treatment with GLP-1 agonists may be more effective than metformin in reducing dementia risk among individuals with type 2 diabetes. Given the high prevalence of both diabetes and dementia in aging populations, this strategy may reduce long-term public health burdens, including healthcare costs, caregiver stress, and institutionalization needs.'– Szu-Yuan Wu, MD, MPH, PhDThe researcher team also discovered that study participants taking GLP-1 agonists had a 25% lower risk of developing non-vascular dementias and a 12% lower chance of developing Alzheimer's disease, compared to participants taking metformin. 'These subtype-specific findings reinforce the mechanistic rationale for GLP-1 agonists in neuroprotection,' Wu said. 'They are known to reduce amyloid-beta accumulation, suppress tau hyperphosphorylation, improve cerebrovascular integrity, and lower systemic inflammation.''These effects are not only theoretical; clinical trials of agents like liraglutide have shown cognitive improvements in patients with early Alzheimer's disease. Our results support that these biological actions may translate into meaningful risk reduction in real-world populations,' he detailed.A novel, effective way of lowering dementia risk?MNT had the opportunity to speak with Michael Snyder, MD, FACS, FASMBS, medical director of the Bariatric Surgery Center at Rose Medical Center, founder and director of the Denver Center for Bariatric Surgery Foundation, and in-house obesity specialist for FuturHealth, about this study. Snyder, who was not involved in the research, commented that these findings are quite significant as an introduction to a novel and seemingly extremely effective way of decreasing the risk of type 2 diabetes related dementia, specifically, Alzheimer's disease and nonvascular dementia. 'Early research has suggested that GLP-1 medications may offer powerful benefits for brain health,' he explained. 'Obesity, insulin resistance, and type 2 diabetes are all known to increase the risk of dementia, largely due to their role in driving inflammation, vascular damage, and other long-term stressors on the brain. By targeting these underlying issues, GLP-1s, which are already widely used to treat obesity and diabetes, may offer indirect protection against cognitive diseases,' Snyder pointed out.'In addition, emerging evidence shows that GLP-1s may have direct neurological effects, influencing memory, cognitive function, and neuroinflammation,' he continued. 'Although promising, long-term studies and clinical trials are needed to fully understand GLP-1s impact on the brain. With that said, GLP-1s could play a pivotal role in preventing or slowing neurodegenerative diseases, marking a major step forward in the future of brain health.'More research needed for definitive conclusionsMNT also spoke to Jennifer Cheng, DO, chief of endocrinology at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, about this research. 'As an endocrinologist who treats type 2 diabetes on a regular basis, I found the study to be thought provoking and an interesting avenue of research,' Cheng, who likewise was not involved in the research, commented. 'The cognitive complications of diabetes can be significant and life debilitating. The protective effect for diabetes is promising and may help with treatment decisions in the future. It is an interesting method of research and can lead to further discoveries.' 'We are discovering new effects of the GLP-1 medications and it is interesting to see the possible protective effects. Patients with diabetes do have increased risk for neurological disorders including vascular issues and dementia. This is just an observational study so there can be no conclusions about the medications being the definitive cause of the decreased risk of Alzheimer's and/or dementia.'– Jennifer Cheng, DO'For research next steps, it would be interesting to see the new GLP-1 medications, and effects of the GLP-1s, studied to see if it is definitive,' Cheng added. 'We cannot conclude that based on an observational study that the GLP-1 was the primary agent to help prevent the cognitive complications of diabetes, but it does warrant further investigation, especially with new GLP-1 medications in development.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abortion pioneer died at 93 in hospital after being diagnosed with dementia
Abortion pioneer died at 93 in hospital after being diagnosed with dementia

BreakingNews.ie

timean hour ago

  • BreakingNews.ie

Abortion pioneer died at 93 in hospital after being diagnosed with dementia

A pioneer of abortion services in the United States died at the age of 93 after being detained under the mental health act at a Dorset hospital after suffering paranoia and delirium having been diagnosed with dementia, an inquest has heard. Dr Horace Hale Harvey III, who was born in New Orleans in December 1931, opened one of the first independent abortion clinics in the US in Manhattan in July 1970 after New York State had reformed its laws. Advertisement The clinic, called Women's Services, provided safe and affordable abortions. In an obituary, the New York Times reported that Dr Harvey had become an abortion provider to 'combat what he felt was an epidemic of unsafe abortions at a time when unmarried women were denied access to contraceptives, and when comprehensive sex education was discouraged'. Dr Harvey, who had a son and a daughter, later moved to the Isle of Wight and worked for public health services there but in 2014 moved to Dorset after his house burned down. The obituary states that Dr Harvey had chosen the Isle of Wight because 'according to his research, it had the highest average temperature and received more hours of sunlight than anywhere else in England'. Advertisement In a statement read to the Bournemouth inquest, his daughter Kate said that her father was 'very determined' to keep healthy by walking a mile and doing 20 squats each day and said he 'enjoyed laughter and making up jokes' as well as activities such as dance, table tennis and snooker. Dr Harvey later worked on the Isle of Wight (Andrew Matthews/PA) She added that he was a scholar who was 'committed to Aristotelian ethics and scientific learning'. The inquest heard that in late 2024, Dr Harvey was diagnosed with Alzheimer's and PTSD after the house fire 10 years earlier. On January 22 2025, he was taken to Dorset County Hospital having suffered a rib fracture in a fall at home. Advertisement After physiotherapists expressed concerns at his ability to understand care instructions, he was assessed by psychiatrists and was detained under the mental health act. Coroner Richard Middleton said that Dr Harvey was increasingly experiencing delirium and paranoia. He said that Dr Harvey was found dead in his hospital bed in the early hours of February 14 and a post-mortem examination found he died of natural causes from ischaemic heart disease and coronary artery disease. The coroner, recording a conclusion of death by natural causes, explained that the inquest had to be held by law because Dr Harvey was formally detained by the state at the time of his death. Advertisement Mr Middleton added: 'I express my deepest condolences to all of Dr Harvey's family and friends for their loss.'

Cambridge study says healthy diets could reduce risk of diabetes
Cambridge study says healthy diets could reduce risk of diabetes

BBC News

time5 hours ago

  • BBC News

Cambridge study says healthy diets could reduce risk of diabetes

Several healthy diets can reduce the risk of type 2 diabetes, regardless of a person's ethnicity, a new study has foundResearchers from the University of Cambridge looked at 33 studies on three different diets featuring 826,000 analysis suggested the eating habits, all of which place a focus on consuming more fruits, vegetables, and whole grains, "can be promoted across all populations".They said the findings "suggest that major ethnic groups benefit equally from higher adherence to these dietary patterns", although more research is needed for specific populations. Researchers said the Mediterranean diet, the Alternative Healthy Eating Index (AHEI) and Dietary Approaches to Stop Hypertension (Dash) were trialled. The study found that the top 10% who adhered to the diets had a significantly lower risk of developing type 2 diabetes. Type 2 diabetes happens when the hormone insulin does not work properly, causing high blood sugar. Treatment for the condition could include lifestyle changes such as healthier eating and exercise to help lower review suggested that the Dash diet reduced the risk of developing the condition by 23%, the Mediterranean by 17% and AHEI linked to a 21% lower benefits of following each diet also did not appear to vary across African, Asian, European, and Hispanic ethnic groups, according to added: "This study strengthens the evidence that the Mediterranean, AHEI, and Dash dietary patterns may reduce the risk of type 2 diabetes across diverse ethnic groups, and that they can be promoted across all populations."The findings will be presented at the European Association for the Study of Diabetes (EASD) in Vienna in September. Follow Cambridgeshire news on BBC Sounds, Facebook, Instagram and X.

Japanese walking: how the latest fitness trend shapes up
Japanese walking: how the latest fitness trend shapes up

Times

time16 hours ago

  • Times

Japanese walking: how the latest fitness trend shapes up

At first there was yoga. Then, there was pilates. Now, social media fitness fanatics have turned to a new exercise trend: Japanese walking. The simple workout, also known as Nihon Aruki in its homeland, boasts a range of health benefits, according to researchers. The exercise involves interval-style bursts of fast and slow walking, alternating between walking at a higher intensity for three minutes and a lower intensity for the next three. The researchers capped the fast intervals at three minutes because that was the point at which many older volunteers started to feel tired. During the fast intervals, people should aim to take longer strides than during the slow intervals. Engaging the arms by bending them at the elbows and swinging them with each step is recommended as a way to help maintain proper form during longer strides. It was developed by Professor Hiroshi Nose and Associate Professor Shizue Masuki at Shinshu University in Matsumoto, Japan, as a way to help elderly citizens get the health benefits experienced by athletes undertaking high-intensity interval training. According to the researchers, the high-intensity walking should be undertaken at a speed where holding a normal conversation is slightly difficult. The lower intensity pace should be light, and normal conversation should be possible. Their initial research, conducted in 2007, compared 'Japanese walking' with normal walking at a continuous speed, for 8,000 steps per day. Those who participated in the study found that those walking at varying speeds experienced weight loss and lower blood pressure. • Am I fit for my age? Exercises for your 30s to your 70s Both leg strength and physical fitness also improved for those undertaking the Japanese walking programme. A later study, conducted by the same researchers in 2018, found that, over a ten-year period, those who did interval walking reported fewer age-related declines in their muscle power and aerobic capacity. Some experts have, however, said that simply walking more, and at more rigorous speeds could boost health, and that this specific walking regime may therefore not have any particular benefits. 'Achieving a certain number of steps per day has also been shown to help people live longer,' Sean Pymer, an Academic Clinical Exercise Physiologist at the University of Hull wrote in The Conversation. • How to hit peak fitness over 40: the midlife rules 'For those aged 60 and older, the target should be around 6,000 to 8,000 steps a day and 8,000 to 10,000 for those aged under 60. Similar evidence does not appear to exist for Japanese walking … yet,' he continued. 'So is this walking trend really the be-all and end-all? Or does it matter less about what exercise you do and more about how often and how hard you do it? The answer is likely to be the latter … We should focus on ensuring we perform regular moderate to vigorous physical activity and make it habitual. If that activity happens to be Japanese walking, then it's a worthwhile choice.' Some scientists, however, suggest the original Japanese study may have been skewed by the decision to only monitor the high-intensity group with accelerometers, not the moderate intensity group. Dr Helga Van Herle, a cardiologist at the University of South Carolina, has said this may have triggered the Hawthorne effect — participants walking faster than they otherwise would have because they knew they were being watched. Even so, experts generally agree that vigorous bursts of activity, even for short periods, are likely to be beneficial. Compared with more classic forms of high-intensity interval training, interval walking is more approachable for some groups, especially those who haven't exercised in a while or who are recovering from injuries that make activities such as running difficult.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store